Shanghai Junshi Biosciences (HKG:1877, SHA:688180) received approval from China's National Medical Products Administration to market toripalimab injection, according to a Hong Kong Stock Exchange filing on May 21.
The drug, trading under the name Tuoyi, is used in combination with bevacizumab for the treatment of unresectable or metastatic hepatocellular carcinoma, the pharmaceutical company said.
Both of the company's Hong Kong and Shanghai shares slipped 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.